Theorem Clinical Research

Decision Resources

Report: Psoriatic arthritis market will reach more than $3.5B in 2023

Thursday, September 11, 2014 01:28 PM

The market for psoriatic arthritis (PsA) therapies will grow nearly 66%, increasing to $3.7 billion in 2023, due to the continued uptake of premium-price biologics and novel therapies expected to launch during the 2013 to 2023 forecast period, according to Burlington, Mass.-based Decision Resources Group.

More... »


Report: clinical trials will continue to play a key role in oncology device market

Wednesday, September 10, 2014 03:03 PM

The U.S. interventional oncology device market will see strong growth, reaching a value of $760 million by 2023, according to Decision Resources Group. Rising cancer incidence rates, combined with the ineffectiveness of chemotherapy and demand for less invasive procedures, will support interventional oncology device uptake.

More... »


Alzheimer's disease market forecast to reach nearly $12B by 2023

Monday, July 21, 2014 03:29 PM

Decision Resources Group has found the market for Alzheimer's disease (AD) therapies will more than triple, reaching nearly $12 billion by 2023, largely due to the forecasted launch of the first disease-modifying therapies (DMTs), a landmark event in AD treatment.

More... »

Report: cancer immunotherapy market to hit $9B globally by 2022

Wednesday, July 9, 2014 12:05 PM

Decision Resources Group reports the immunotherapy market will experience considerable growth through 2022, increasing from $1.1 billion in 2012 to nearly $9 billion in 2022 (corresponding to 23.8% annual growth) in the U.S., France, Germany, Italy, Spain, U.K. and Japan.

More... »

Report: U.S. Alzheimer's imaging agent market will grow as reimbursement improves

Thursday, February 13, 2014 03:03 PM

The U.S. Alzheimer's imaging agent market will grow dramatically over the next 10 years, according to Decision Resources Group. Currently, Eli Lilly's Amyvid, launched in June 2013, is the only FDA-approved product available, but GE Healthcare, Piramal Enterprises and Navidea Biopharmaceuticalsare all poised to launch products in the U.S. in the next few years.

More... »

Decision Resources Group acquires Relay Technology Management

Wednesday, January 8, 2014 01:31 PM

Piramal Enterprises' information management subsidiary, Decision Resources Group, a research and advisory firm focusing on high-value healthcare insights and analytics, has acquired Relay Technology Management, a data analytics company focused on the life sciences industry.

More... »

Report: Pharma should factor medication adherence into drug development

Monday, December 2, 2013 10:34 AM

Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, has a new strategic insights report that found in response to widespread medication nonadherence, pharmaceutical companies should factor medication adherence interventions into their drug development process.

More... »

Report: use of biomarkers outside oncology trials increasing

Thursday, November 14, 2013 11:00 AM

Decision Resources, a research and advisory firm focusing on pharmaceutical and healthcare issues, found while most of the biomarker-drug success stories are in oncology, biomarkers play a critical role in pharmaceutical development of chronic conditions and their use in clinical trials of drugs outside of oncology is building.

More... »

Increasing affluence, legislative reforms are transforming Poland’s pharmaceutical market

Monday, October 28, 2013 02:22 PM

Decision Resources has found that Poland’s increasing affluence—as well as its reforms and policy initiatives on healthcare quality, access, privatization and financing—have contributed to growth in the country’s pharmaceutical market during the last decade.

More... »

Report: Increase in Biopharma new product launches originating from in-licensing deals

Friday, October 18, 2013 01:51 PM

Decision Resources, a research and advisory firms for pharmaceutical and healthcare issues, reports that biopharma companies industry-wide are increasingly moving away from in-house research and toward acquisitive strategies to build their portfolios and grow sales. According to findings from the Strategic Insights report, the fraction of new product launches that originate from in-licensing has increased dramatically over the last decade. In 2012, 53% of new product launches were in-licensed during development, as compared to an average of 32% between 2003 and 2012.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 29

WCG sees ePharmaSolutions’ clinical trial portal as the next step in the data evolution, company mission

Cutting-edge advertising can ‘break through the clutter’ for successful patient recruitment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs